Name | 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine |
Synonyms | Abt199 int3 1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine 1-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]Piperazine ''1-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazine'' 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine 1-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazine dihydrochloride salt |
CAS | 1228780-72-0 |
Molecular Formula | C19H27ClN2 |
Molar Mass | 318.8841 |
Density | 1.072±0.06 g/cm3(Predicted) |
Boling Point | 421.2±45.0 °C(Predicted) |
pKa | 9.21±0.10(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
Use | This product is for scientific research only and shall not be used for other purposes. |
Venetoclax (venetoclax) is the first selective inhibitor targeting B- cell lymphoma factor 2(BCL-2), developed by AbbVie Inc and Genentech, a subsidiary of Roche Group in Switzerland. On January 16, 2015, it was awarded the status of breakthrough drug and priority review by the U.S. Food and Drug Administration (FDA). Through the accelerated approval process, it was approved for listing on April 11, 2016. It is suitable for patients with treated chronic lymphocytic leukemia and refractory or relapsed deletion of 17p mutant gene.